Risk of breast cancer in male BRCA2 carriers.

Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer Risk. J Clin Oncol (2015) 1.08

Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat (2010) 1.06

Androgen receptor polyglutamine tract length in Egyptian male breast cancer patients. Breast Cancer Res Treat (2011) 0.83

Differential expression of growth factor receptors and membrane-bound tumor markers for imaging in male and female breast cancer. PLoS One (2013) 0.82

Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients. Breast Dis (2011) 0.80

The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. Oncotarget (2016) 0.80

Reduced life expectancy seen in hereditary diseases which predispose to early-onset tumors. Appl Clin Genet (2013) 0.75

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2016) 0.75

Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas. PLoS One (2016) 0.75

Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing. Cancer Biol Med (2016) 0.75

BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Ther Adv Med Oncol (2017) 0.75

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67

Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem (2000) 5.58

Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet (2001) 4.71

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87

The use of the Oxford hip and knee scores. J Bone Joint Surg Br (2007) 3.77

A maternally methylated CpG island in KvLQT1 is associated with an antisense paternal transcript and loss of imprinting in Beckwith-Wiedemann syndrome. Proc Natl Acad Sci U S A (1999) 3.37

Use of prenatal chromosomal microarray: prospective cohort study and systematic review and meta-analysis. Ultrasound Obstet Gynecol (2013) 3.28

Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J (2000) 3.13

A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet (2004) 3.10

Clinical features and natural history of Beckwith-Wiedemann syndrome: presentation of 74 new cases. Clin Genet (1994) 3.04

Molecular phylogeny of the genus Frankia and related genera and emendation of the family Frankiaceae. Int J Syst Bacteriol (1996) 2.96

Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat (1996) 2.80

Gigantomastia--a classification and review of the literature. J Plast Reconstr Aesthet Surg (2007) 2.72

Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J Med Genet (2006) 2.68

National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis (1999) 2.63

Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet (2001) 2.56

Risk behaviour, anti-HIV and anti-hepatitis B core prevalence in clinic and non-clinic samples of gay men in England, 1991-1992. AIDS (1993) 2.50

Beckwith-Wiedemann syndrome and assisted reproduction technology (ART). J Med Genet (2003) 2.48

Uptake of screening and prevention in women at very high risk of breast cancer. Lancet (2001) 2.45

Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet (1999) 2.41

Familial gastric cancer: overview and guidelines for management. J Med Genet (1999) 2.38

The Arabidopsis MALE STERILITY1 (MS1) gene is a transcriptional regulator of male gametogenesis, with homology to the PHD-finger family of transcription factors. Plant J (2001) 2.29

Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer (1998) 2.27

Imprinting mutations in the Beckwith-Wiedemann syndrome suggested by altered imprinting pattern in the IGF2-H19 domain. Hum Mol Genet (1995) 2.27

Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet (2003) 2.24

Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene (2001) 2.22

Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res (2001) 2.12

Prevalence and incidence of adults consulting for shoulder conditions in UK primary care; patterns of diagnosis and referral. Rheumatology (Oxford) (2005) 2.07

Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A (2010) 2.05

Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet (2009) 2.05

Septic shock: an analysis of outcomes for patients with onset on hospital wards versus intensive care units. Crit Care Med (1998) 2.04

Imprinting in clusters: lessons from Beckwith-Wiedemann syndrome. Trends Genet (1997) 2.01

Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer (2002) 1.95

The VHL tumour-suppressor gene paradigm. Trends Genet (1998) 1.94

Conventional versus laparoscopic surgery for acute appendicitis. Br J Surg (1993) 1.93

Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91

Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet (2008) 1.90

Risk of strangulation in groin hernias. Br J Surg (1991) 1.90

Additional information from array comparative genomic hybridization technology over conventional karyotyping in prenatal diagnosis: a systematic review and meta-analysis. Ultrasound Obstet Gynecol (2011) 1.85

CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene (1996) 1.85

Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA (1995) 1.83

Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol (2001) 1.82

The genetics of paragangliomas: a review. Clin Otolaryngol (2007) 1.77

Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation. J Med Genet (1999) 1.74

Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene (2010) 1.69

Silencing of CDKN1C (p57KIP2) is associated with hypomethylation at KvDMR1 in Beckwith-Wiedemann syndrome. J Med Genet (2003) 1.68

Beckwith-Wiedemann syndrome. J Med Genet (1994) 1.67

Intermediates in the formation of mouse 20S proteasomes: implications for the assembly of precursor beta subunits. EMBO J (1997) 1.67

Simulated car crashes and crash predictors in drivers with Alzheimer disease. Arch Neurol (1997) 1.65

Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation. Arch Ophthalmol (1999) 1.64

Germline SDHD mutation in familial phaeochromocytoma. Lancet (2001) 1.62

Familial breast cancer: an investigation into the outcome of treatment for early stage disease. Fam Cancer (2001) 1.62

A genetic register for von Hippel-Lindau disease. J Med Genet (1996) 1.61

Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet (1998) 1.61

Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology (2008) 1.60

Comparison of thrombelastography with common coagulation tests. Thromb Haemost (1981) 1.58

Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3' APC gene mutation. Hum Mol Genet (1996) 1.57

Effect of the total motile sperm count on the efficacy and cost-effectiveness of intrauterine insemination and in vitro fertilization. Fertil Steril (2001) 1.57

Imprinting mutation in the Beckwith-Wiedemann syndrome leads to biallelic IGF2 expression through an H19-independent pathway. Hum Mol Genet (1996) 1.57

The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1986) 1.55

Imprinting of IGF2 and H19: lack of reciprocity in sporadic Beckwith-Wiedemann syndrome. Hum Mol Genet (1997) 1.54

Regular partners and risky behaviour: why do gay men have unprotected intercourse? AIDS Care (1994) 1.54

Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. Am J Hum Genet (1997) 1.54

Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene (2010) 1.52

Breast cancer teams: the impact of constitution, new cancer workload, and methods of operation on their effectiveness. Br J Cancer (2003) 1.51

Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome. J Med Genet (2000) 1.51

The UK Northern region genetic register for familial adenomatous polyposis coli: use of age of onset, congenital hypertrophy of the retinal pigment epithelium, and DNA markers in risk calculations. J Med Genet (1991) 1.51

A review of biological factors implicated in abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg (2005) 1.51

Molecular genetic tests in surgical management of familial adenomatous polyposis. Lancet (1997) 1.50

Recurrent germline mutation in MSH2 arises frequently de novo. J Med Genet (2000) 1.49

Syntenic organization of the mouse distal chromosome 7 imprinting cluster and the Beckwith-Wiedemann syndrome region in chromosome 11p15.5. Hum Mol Genet (1998) 1.49

Assisted reproductive therapies and imprinting disorders--a preliminary British survey. Hum Reprod (2005) 1.48

Mapping of a novel locus for achromatopsia (ACHM4) to 1p and identification of a germline mutation in the alpha subunit of cone transducin (GNAT2). J Med Genet (2002) 1.44

Screening by mammography, women with a family history of breast cancer. Eur J Cancer (1998) 1.44

Achromatopsia caused by novel mutations in both CNGA3 and CNGB3. J Med Genet (2004) 1.44

Functional outcome measures in contemporary stroke trials. Int J Stroke (2009) 1.43

Pull-out strength of Caspar cervical screws. Neurosurgery (1992) 1.42

Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers. Br J Cancer (2004) 1.42

Cloning and characterization of a corepressor and potential component of the nuclear hormone receptor repression complex. Proc Natl Acad Sci U S A (1997) 1.41

The end of the p value? Br Heart J (1988) 1.41

Colonic Crohn's disease and use of oral contraception. Br Med J (Clin Res Ed) (1984) 1.40

Dialysis amyloid presenting as acute arthritis. Nephron (1988) 1.40

Colonoscopy screening compliance and outcomes in patients with Lynch syndrome. Colorectal Dis (2015) 1.40

Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer (2012) 1.39

Vascular surgery in smokers. Smokers must be allowed to decide. BMJ (1994) 1.39

Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour. Br J Cancer (2005) 1.39

Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res (2001) 1.35

The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Oncogene (2001) 1.34

Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol (2001) 1.32

Primary total hip replacement surgery: a systematic review of outcomes and modelling of cost-effectiveness associated with different prostheses. Health Technol Assess (1998) 1.32

Vision and cognition in Alzheimer's disease. Neuropsychologia (2000) 1.31

Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) robustly detects and distinguishes 11p15 abnormalities associated with overgrowth and growth retardation. J Med Genet (2007) 1.30

Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet (2005) 1.29

Atherosclerotic renovascular disease causing renal impairment--a case for treatment. Clin Nephrol (1989) 1.28

Mosaic uniparental disomy in Beckwith-Wiedemann syndrome. J Med Genet (1994) 1.28

Risk perception and cancer worry: an exploratory study of the impact of genetic risk counselling in women with a family history of breast cancer. J Med Genet (2001) 1.28